MY201774A - Multispecific antibodies specifically binding to zika virus epitopes and uses thereof - Google Patents

Multispecific antibodies specifically binding to zika virus epitopes and uses thereof

Info

Publication number
MY201774A
MY201774A MYPI2019007495A MYPI2019007495A MY201774A MY 201774 A MY201774 A MY 201774A MY PI2019007495 A MYPI2019007495 A MY PI2019007495A MY PI2019007495 A MYPI2019007495 A MY PI2019007495A MY 201774 A MY201774 A MY 201774A
Authority
MY
Malaysia
Prior art keywords
zika virus
multispecific antibodies
specifically binding
antibodies specifically
virus epitopes
Prior art date
Application number
MYPI2019007495A
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of MY201774A publication Critical patent/MY201774A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
MYPI2019007495A 2017-08-31 2018-08-31 Multispecific antibodies specifically binding to zika virus epitopes and uses thereof MY201774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/071891 WO2019042555A1 (en) 2017-08-31 2017-08-31 MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
PCT/EP2018/073489 WO2019043166A1 (en) 2017-08-31 2018-08-31 MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MY201774A true MY201774A (en) 2024-03-16

Family

ID=59811299

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019007495A MY201774A (en) 2017-08-31 2018-08-31 Multispecific antibodies specifically binding to zika virus epitopes and uses thereof

Country Status (21)

Country Link
US (2) US11926658B2 (enExample)
EP (1) EP3676290A1 (enExample)
JP (2) JP7244489B2 (enExample)
KR (1) KR20200042499A (enExample)
CN (2) CN116693668A (enExample)
AU (1) AU2018322842A1 (enExample)
BR (1) BR112020000619A2 (enExample)
CA (1) CA3070780A1 (enExample)
CL (1) CL2020000467A1 (enExample)
CO (1) CO2020002060A2 (enExample)
CR (1) CR20200087A (enExample)
DO (1) DOP2020000043A (enExample)
EA (1) EA202090559A1 (enExample)
EC (1) ECSP20014362A (enExample)
IL (1) IL271515A (enExample)
MX (1) MX2020002181A (enExample)
MY (1) MY201774A (enExample)
PE (1) PE20200888A1 (enExample)
PH (1) PH12020550025A1 (enExample)
SG (1) SG11202000206SA (enExample)
WO (2) WO2019042555A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019042555A1 (en) * 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
MX2022005498A (es) * 2019-11-07 2022-08-11 Inst Microbiology Cas Vacuna del zika/dengue y aplicación de la misma.
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021236225A1 (en) * 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
EP4153222A1 (en) * 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
CN115697392A (zh) * 2020-06-28 2023-02-03 神州细胞工程有限公司 一种降低病毒ade效应的方法
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN114958747B (zh) * 2022-06-08 2024-08-20 中国科学院动物研究所 一种多能干细胞诱导产生兴奋性和抑制性神经元的方法
WO2025107050A1 (pt) * 2023-11-23 2025-05-30 Imunotera Soluções Terapêuticas Ltda Anticorpo monoclonal, vetor de expressão, uso, composição farmacêutica, processo para produção, método de prevenção e/ou tratamento de infecções por flavivírus e kit para a detecção de vírus da zika e da dengue
CN119119256B (zh) * 2024-09-28 2025-07-18 宁波大学 一种乙型脑炎病毒和寨卡病毒的单克隆抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
ES2923641T3 (es) * 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
EP2980099A1 (en) * 2014-07-31 2016-02-03 Bernhard-Nocht-Institut für Tropenmedizin Compositions and methods for detecting flaviviridae infections
MY187459A (en) 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
KR20180127397A (ko) 2016-03-11 2018-11-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생약독화된 지카 바이러스 백신
CN105954512A (zh) 2016-06-01 2016-09-21 卢氏实验室公司 一种快速免疫层析法检测塞卡病毒Zika virus的检测条
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
CN110066333B (zh) 2016-08-10 2020-09-04 中国科学院微生物研究所 一种寨卡病毒特异性中和抗体及其应用
US20190324040A1 (en) * 2016-10-29 2019-10-24 University Of Miami Zika virus antibodies
US11021533B2 (en) * 2016-11-02 2021-06-01 Vanderbilt University Human Zika virus antibodies and methods of use therefor
CN106841601A (zh) 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 寨卡病毒多片段融合蛋白的制备及IgG/IgM抗体检测试剂盒
CN106885903B (zh) * 2017-03-08 2018-12-28 中国人民解放军军事医学科学院基础医学研究所 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用
WO2019042555A1 (en) * 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

Also Published As

Publication number Publication date
PH12020550025A1 (en) 2021-02-15
US20200317755A1 (en) 2020-10-08
ECSP20014362A (es) 2020-04-22
US11926658B2 (en) 2024-03-12
WO2019042555A1 (en) 2019-03-07
AU2018322842A1 (en) 2020-01-16
CL2020000467A1 (es) 2020-06-19
BR112020000619A2 (pt) 2020-07-14
CA3070780A1 (en) 2019-03-07
PE20200888A1 (es) 2020-09-03
KR20200042499A (ko) 2020-04-23
JP2023071956A (ja) 2023-05-23
CN116693668A (zh) 2023-09-05
JP2020531000A (ja) 2020-11-05
EP3676290A1 (en) 2020-07-08
SG11202000206SA (en) 2020-03-30
DOP2020000043A (es) 2020-09-15
CO2020002060A2 (es) 2020-06-09
WO2019043166A1 (en) 2019-03-07
CN111344302B (zh) 2023-03-10
JP7244489B2 (ja) 2023-03-22
CR20200087A (es) 2020-08-07
IL271515A (en) 2020-02-27
MX2020002181A (es) 2020-07-20
CN111344302A (zh) 2020-06-26
EA202090559A1 (ru) 2020-06-17
US20240254207A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
ZA201807467B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
SA522431756B1 (ar) Tigit أجسام مضادة لـ
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EP4417263A3 (en) Cd3 binding antibodies
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
JO3663B1 (ar) الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
EA201891594A1 (ru) Антитела к il-17c
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
TH1801007229A (th) แอนติบอดีที่ใหม่ที่จับอย่างจำเพาะกับอิพิโทปของซิกาไวรัสและการใช้งานของสิ่งนั้น (novel antibodies specifically binding to zika virus epitopes and uses thereof)